传染病药物市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

传染病药物市场按疾病(艾滋病毒、流感、肝炎、结核病、疟疾等)、治疗和地理划分

市场快照

Infectious Disease Drugs Market Size
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.3 %
Infectious Disease Drugs Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

传染病药物市场增长的主要因素包括各种政府和非营利组织提高认识活动、传染病流行率增加以及研发资金增加。

预计传染病流行率的上升将在预测期内推动市场的整体增长。据世界卫生组织 (WHO) 估计,2018 年,全球有近 3790 万人感染了艾滋病毒。已经确定,这种流行率大部分发生在低收入和中等收入国家,估计有 66% 的人生活在撒哈拉以南非洲。

同样,根据世卫组织的 2017 年全球结核病报告,2016 年报告了大约 630 万新发结核病 (TB) 病例。该报告还估计,新病例占 1040 万结核病病例估计发病率的 61%。因此,预计传染病病例的增加将增加对传染病药物的需求,从而导致市场的高速增长。

报告范围

根据本报告的范围,传染病是由细菌、病毒、真菌或寄生虫等生物引起的疾病,用于治疗传染病的药物种类繁多。 

By Disease
HIV
Influenza
Hepatitis
Tuberculosis
Malaria
Other
By Treatment
Antibacterial
Antiviral
Antiparasitic
Other
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

疟疾部分预计将在预测期内占有重要的市场份额

疟疾和其他感染的高流行率;增加这些情况的发生率;传染病预防和诊断支出的增加可能是推动该市场增长的关键因素。根据世界卫生组织的报告,非洲的疟疾发病率最高。因此,在 2000 年至 2015 年期间,疟疾干预措施的扩大帮助全球疟疾发病率降低了 37%,非洲降低了 42%。

全球范围内还开展了各种以疾病预防为重点的举措。此外,政府、私人和非营利组织也致力于加强对这些疾病的管理。因此,所有这些因素都有望推动整体市场增长。

Infectious Disease Drugs Market Share

预计北美将在预测期内占据最大的市场份额

由于传染病流行率的上升和更好的医疗基础设施的存在,预计美国将成为最大的传染病药物市场。根据美国疾病控制和预防中心 (CDC) 的数据,2017 年,美国共报告了 9,093 例新的结核病 (TB) 病例,发病率为每 100,000 人 2.8 例。

此外,美国的抗生素处方率相对较高。此外,根据特定状态的提供者,趋势差异很大。此外,美国艾滋病毒的流行率不断上升,对新疾病治疗的批准也在增加,这有望促进市场的增长。因此,由于上述所有因素,预计市场在预测期内将出现高速增长。

Infectious Disease Drugs Market Growth

竞争格局

由于存在各种市场参与者,所研究的市场是一个分散的市场。一些市场参与者是艾伯维公司、勃林格殷格翰有限公司、吉利德科学公司、葛兰素史克公司、杨森制药、默克公司、诺华公司、辉瑞公司、赛诺菲公司和武田制药有限公司。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Awareness Activities by Various Government and Non-profit Organizations

      2. 4.2.2 Increasing Prevalence of Infectious Diseases

      3. 4.2.3 Rising Funding for the Research and Development

    3. 4.3 Market Restraints

      1. 4.3.1 Low Penetration Rates of Diagnosis and Treatment in Developing Countries

      2. 4.3.2 Side Effects of the Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Disease

      1. 5.1.1 HIV

      2. 5.1.2 Influenza

      3. 5.1.3 Hepatitis

      4. 5.1.4 Tuberculosis

      5. 5.1.5 Malaria

      6. 5.1.6 Other

    2. 5.2 By Treatment

      1. 5.2.1 Antibacterial

      2. 5.2.2 Antiviral

      3. 5.2.3 Antiparasitic

      4. 5.2.4 Other

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc.

      2. 6.1.2 Boehringer Ingelheim GmbH

      3. 6.1.3 Gilead Sciences, Inc.

      4. 6.1.4 GlaxoSmithKline plc

      5. 6.1.5 Janssen Pharmaceutical (Johnson & Johnson)

      6. 6.1.6 Merck & Co., Inc.

      7. 6.1.7 Novartis AG

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Sanofi SA

      10. 6.1.10 Takeda Pharmaceutical Company Limited

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Infectious Disease Drugs Market market is studied from 2018 - 2026.

The Infectious Disease Drugs Market is growing at a CAGR of 4.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

AbbVie Inc, Gilead Sciences, Inc., Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc. are the major companies operating in Infectious Disease Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!